Clinical Trials Browser

Has results × Triple Negative Breast Neoplasms × exemestane × Clear all

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2 Completed

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms